CRISPR Therapeutics.
company in Basel, Switzerland
- Reports this week
- 0
- Active events
- 0
- Connections
- 78
What's happening
Earlier this month
-
CRISPR Therapeutics presented clinical data at the American Society of Hematology meeting on November 4, 2026.Some support1 report
-
MarketBeat summarized current investment recommendations for CRISPR Therapeutics on November 3, 2026.Some support1 report
-
CRISPR Therapeutics and Vertex Pharmaceuticals split profits and costs for Casgevy, while CRISPR plans to present pipeline data at the AHA meeting.Some support1 report
-
CRISPR Therapeutics and Vertex Pharmaceuticals received FDA approval for their gene therapy Casgevy for sickle cell disease.Some support3 reports
-
Orna Therapeutics was acquired by Eli Lilly and Company, a development within the RNA therapeutics sector.Some support1 report
-
CRISPR Therapeutics, Eli Lilly, and Johnson & Johnson are noted as major holdings in health care ETFs.Some support1 report
-
CRISPR Therapeutics formed a strategic partnership with Vertex Pharmaceuticals.Well supported7 reports1 development inside
-
CRISPR Therapeutics announced that A.J. Silver will succeed Raju Prasad as CFO, following Silver's time at Ernst & Young LLP.Some support1 report
One to three months ago
-
CRISPR Therapeutics is discussing commercial priorities and expanding treatment access into new markets with an investment bank.Some support1 report1 development inside
-
CRISPR Therapeutics and Scribe Therapeutics presented at a Morgan Stanley conference, highlighting their competition in gene-editing therapeutics.Some support1 report
-
CRISPR Therapeutics presented durability data on gene therapy at the European Society of Cardiology (ESC) Congress on August 28, 2026.Some support1 report
Gone quiet
No new reports in 90+ days-
CRISPR Therapeutics and Microsoft are noted as major players in technology sectors.Some support1 report
-
CRISPR Therapeutics and Vertex Pharmaceuticals successfully developed Casgevy in collaboration as part of their strategic partnership.Well supported18 reports
-
CRISPR and Vertex Pharmaceuticals developed the CASGEVY therapy, noting growing treatment centers in Europe and the US.Some support1 report
-
CRISPR Therapeutics issued press releases from Zug and Boston on June 26, 2025.Speculative1 report
-
H.C. Wainwright raised its price target on CRISPR Therapeutics (CRSP) on August 25, 2025, noting that tariffs related to the Trump era are benefiting AI stocks, and CRSP is held by Cathie Wood.Some support9 reports
-
CRISPR Therapeutics stock performance and Zacks Rank rating were reported on July 26, 2025, within the biomedical sector.Some support5 reports1 development inside
-
Both CRISPR Therapeutics and Wave Life Sciences operate within the medical/biomedical industry.Some support1 report
-
CRISPR Therapeutics and the broader biomedical and genetics industry were operating within the medical sector, with stock performance noted against the S&P 500 on July 16, 2025.Some support1 report
-
Joby Aviation is pioneering the era of flying taxis, while CRISPR Therapeutics has made a major breakthrough in how to repair damaged DNA.Some support1 report
-
A company acknowledged the foundational work of Emmanuelle Charpentier and Jennifer Doudna, refining their contributions to the field.Some support2 reports
-
CRISPR Therapeutics, Castle Biosciences, and Selective Insurance Group received downward earnings estimate revisions on August 1, 2025.Some support2 reports
-
CRISPR Therapeutics achieved a significant performance milestone by outpacing the industry decline on August 23, 2025.Well supported4 reports
-
A strategic collaboration agreement was signed in May between CRISPR Therapeutics and Sirius Therapeutics.Some support1 report
No events began in the chosen period. Widen it, or reset.
What's reaching CRISPR Therapeutics
Events traced to CRISPR Therapeutics, step by step, newest firstAround CRISPR Therapeutics this week
News at the entities that move CRISPR Therapeutics most-
Vertex Pharmaceuticals StructuralInvestors are comparing the growth potential and cash flows of Vertex Pharmaceuticals and BioNTech.Moves CRISPR Therapeutics
-
FDA StructuralFDA issued a warning letter to NeoGen regarding a product quality defect on October 7, 2026.Moves CRISPR Therapeutics
-
Europe StructuralUS bases in Europe are being utilized for military operations related to the war with Iran.Moves CRISPR Therapeutics
-
MarketBeat Mentioned togetherDanske Bank and Farmers & Merchants Bancorp Inc. are being compared as finance companies, with MarketBeat providing analyst ratings for the latter.Moves CRISPR Therapeutics
-
Ark Invest StructuralArk Invest and BlackRock are partnering with tokenization specialist Securitize, with their assets being tracked in options markets.Moves CRISPR Therapeutics
-
Morgan Stanley OperationalBaird lowered its price target for Nvidia, Morgan Stanley took it off its Top Pick list, and Jim Cramer predicted shares may not find a low.Moves CRISPR Therapeutics
Connections
The 33 strongest of 78, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Vertex Pharmaceuticals Structural
CRISPR and Vertex maintain a strategic partnership for the joint development, commercialization, and shared profitability of the gene therapy Casgevy.
-
FDA Structural
The FDA formally regulates and approves CRISPR Therapeutics' gene-editing treatments.
-
Vertex Operational
CRISPR Therapeutics and Vertex are engaged in a strategic partnership for the joint development and commercialization of the Casgevy gene therapy.
-
A.J. Structural
A.J. Silver is slated to succeed the current CFO of CRISPR Therapeutics.
-
Ark Invest Structural
Ark Invest holds CRISPR Therapeutics as a significant portfolio asset.
-
Morgan Stanley Operational
Morgan Stanley provides financial ratings, price targets, and commercial advisory services to CRISPR Therapeutics.
-
Beam Therapeutics Operational
Both companies are actively competing in the gene-editing space, developing therapies for blood disorders.
-
Intellia Therapeutics Operational
Two companies actively compete in the gene-editing space utilizing CRISPR/Cas9 technology.
Show all 33 connections
-
Europe Structural
CRISPR Therapeutics' market presence and authorized treatment centers in Europe are dependent on regulatory approvals and market access provided by the European jurisdiction.
-
Cathie Wood Transactional
CRISPR Therapeutics is held as an investment within Cathie Wood's portfolio, evidenced by recent purchases.
-
Eli Lilly and Company Operational
CRISPR Therapeutics and Eli Lilly compete as high-growth biotech stocks in the healthcare market.
-
Norges Bank Transactional
Norges Bank acquired a new position in the company's share capital.
-
Scribe Therapeutics Operational
The two companies are actively competing against each other in the gene-editing therapeutics market.
-
MarketBeat Mentioned together
MarketBeat provides financial tracking, ratings, and data coverage for CRISPR Therapeutics.
-
Western Europe Operational
CRISPR Therapeutics is actively seeking to expand its treatment access and market presence within the various markets of Western Europe.
-
Chiesi Mentioned together
The entities are co-mentioned as mid-to-mega-cap healthcare stocks within the market context.
-
Benzinga Mentioned together
Benzinga reports on and tracks the stock rating of CRISPR Therapeutics.
-
U.K. Structural
CRISPR Therapeutics' drug CASGEVY received regulatory approval in the U.K. for children.
-
CureVac Mentioned together
Both companies are co-mentioned as operating within the biopharmaceutical healthcare sector.
-
Alnylam Pharmaceuticals Operational
CRISPR Therapeutics and Alnylam Pharmaceuticals actively compete in the development of RNA therapeutics.
-
Nvidia Mentioned together
Both companies are frequently cited together as examples of high-growth technology plays in market coverage.
-
Citigroup Mentioned together
Citigroup provides investment ratings and market coverage on CRISPR Therapeutics.
-
Microsoft Mentioned together
The companies are thematically grouped as major players in technology sectors.
-
American Heart Association Mentioned together
CRISPR Therapeutics is scheduled to present its pipeline data at an American Heart Association meeting.
-
American Society of Hematology Operational
CRISPR Therapeutics actively presents clinical data at the American Society of Hematology meeting.
-
Boston Shared context
CRISPR Therapeutics maintains operational and subsidiary presence within the city of Boston.
-
European Society of Cardiology Shared context
CRISPR Therapeutics presented its gene therapy durability data at the ESC Congress.
-
Raju Structural
Raju Prasad served as the Chief Financial Officer of CRISPR Therapeutics.
-
Ali Behbahani Transactional
Ali Behbahani, a director, sold a significant portion of CRISPR Therapeutics stock.
-
Bahrain Shared context
CRISPR Therapeutics' drug CASGEVY received regulatory approval for younger children in Bahrain.
-
Middle East Shared context
CRISPR Therapeutics operates within the Middle East region to deliver its products to patients.
-
United Arab Emirates Shared context
CRISPR Therapeutics' drug CASGEVY received regulatory approval within the United Arab Emirates.
-
Bitcoin None
No evidence was provided regarding any relationship between CRISPR Therapeutics and Bitcoin.
History
Events by the month they beganNovember 2026
4 events- CRISPR Therapeutics presented clinical data at the American Society of Hematology meeting on November 4, 2026.
- MarketBeat summarized current investment recommendations for CRISPR Therapeutics on November 3, 2026.
- CRISPR Therapeutics and Vertex Pharmaceuticals split profits and costs for Casgevy, while CRISPR plans to present pipeline data at the AHA meeting.
- Orna Therapeutics was acquired by Eli Lilly and Company, a development within the RNA therapeutics sector.
October 2026
2 eventsSeptember 2026
2 eventsShow 2 earlier months
August 2026
2 eventsJune 2026
14 events- CRISPR Therapeutics and Vertex Pharmaceuticals received FDA approval for their gene therapy Casgevy for sickle cell disease.
- CRISPR Therapeutics formed a strategic partnership with Vertex Pharmaceuticals.
- CRISPR Therapeutics and Vertex Pharmaceuticals successfully developed Casgevy in collaboration as part of their strategic partnership.
- CRISPR and Vertex Pharmaceuticals developed the CASGEVY therapy, noting growing treatment centers in Europe and the US.
- CRISPR Therapeutics issued press releases from Zug and Boston on June 26, 2025.
- H.C. Wainwright raised its price target on CRISPR Therapeutics (CRSP) on August 25, 2025, noting that tariffs related to the Trump era are benefiting AI stocks, and CRSP is held by Cathie Wood.
- CRISPR Therapeutics stock performance and Zacks Rank rating were reported on July 26, 2025, within the biomedical sector.
- Both CRISPR Therapeutics and Wave Life Sciences operate within the medical/biomedical industry.
- CRISPR Therapeutics and the broader biomedical and genetics industry were operating within the medical sector, with stock performance noted against the S&P 500 on July 16, 2025.
- Joby Aviation is pioneering the era of flying taxis, while CRISPR Therapeutics has made a major breakthrough in how to repair damaged DNA.
- A company acknowledged the foundational work of Emmanuelle Charpentier and Jennifer Doudna, refining their contributions to the field.
- CRISPR Therapeutics, Castle Biosciences, and Selective Insurance Group received downward earnings estimate revisions on August 1, 2025.
- CRISPR Therapeutics achieved a significant performance milestone by outpacing the industry decline on August 23, 2025.
- A strategic collaboration agreement was signed in May between CRISPR Therapeutics and Sirius Therapeutics.